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Several hemolytic markers are available to guide the differential diagnosis and to monitor treatment of hemolytic conditions.
They include increased reticulocytes, an indicator of marrow compensatory response, elevated lactate dehydrogenase, a marker
of intravascular hemolysis, reduced haptoglobin, and unconjugated hyperbilirubinemia. The direct antiglobulin test is the
cornerstone of autoimmune forms, and blood smear examination is fundamental in the diagnosis of congenital membrane
defects and thrombotic microangiopathies. Marked increase of lactate dehydrogenase and hemosiderinuria are typical of
intravascular hemolysis, as observed in paroxysmal nocturnal hemoglobinuria, and hyperferritinemia is associated with chronic
hemolysis. Prosthetic valve replacement and stenting are also associated with intravascular and chronic hemolysis. Compensatory
reticulocytosis may be inadequate/absent in case of marrow involvement, iron/vitamin deficiency, infections, or autoimmune
reaction against bone marrow-precursors. Reticulocytopenia occurs in 20–40% of autoimmune hemolytic anemia cases and is a
poor prognostic factor. Increased reticulocytes, lactate dehydrogenase, and bilirubin, as well as reduced haptoglobin, are observed in
conditions other than hemolysis that may confound the clinical picture. Hemoglobin defines the clinical severity of hemolysis, and
thrombocytopenia suggests a possible thrombotic microangiopathy or Evans’ syndrome. A comprehensive clinical and laboratory
evaluation is advisable for a correct diagnostic and therapeutic workup of the different hemolytic conditions.
1. Introduction
The term hemolysis refers to the destruction of the red blood
cells (RBC) and accounts for a wide range of laboratory and
clinical conditions, both physiological and pathological. It is
also used to address situations in which erythrocytes half-life
is diminished because ofmechanical, chemical, autoimmune,
or infective causes. If RBC destruction rate is high enough
to determine a decrease in hemoglobin values below the
normal range, hemolytic anemia occurs. This peripheral
destruction/loss driven anemia, together with hemorrhage
and sequestration forms, differs from anemia due to bone
marrow erythrocyte production impairment (pure red cell
aplasia, myelodysplasia, myelophthisis, other hematologic
malignancies, and iron or vitamin deficiency) for alterations
of laboratory markers, acuteness of onset, and treatment
strategies.
A synthetic diagnostic flowchart of hemolytic anemia
is shown in Figure 1 and includes firstly the distinction
between congenital and acquired causes through a careful
patient’s and family medical history. Moreover, it is essential
to distinguish the acute or chronic characteristics of anemia,
the features of intra- or extravascular hemolysis, and the
presence of extrahematological signs. Microscopic blood
smear examination, although not routinely done nowadays,
is still fundamental when performed by an expert operator
and sometimes is determinant for the diagnosis, particularly
in congenital forms. As regards acquired hemolytic anemia,
the direct antiglobulin test (DAT) is the cornerstone for the
diagnosis, enabling the distinction of autoimmune hemolytic
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Figure 1: Diagnostic flowchart for hemolytic diseases. If the diagnostic flowchart turns negative for congenital hemolytic anemia, reconsider
acquired causes and vice versa. RBC: red blood cells; AIHA: autoimmune hemolytic anemia; DHTR: delayed hemolytic transfusion reactions;
CDA: congenital dyserythropoietic anemia; PNH: paroxysmal nocturnal hemoglobinuria.
anemia (AIHA) in warm forms (∼70% of cases, DAT positive
for IgG or IgG + C), cold agglutinin disease (CAD) (∼20%
of patients, DAT positive for C), and mixed forms (<10% of
cases, DAT positive for IgG and C, with coexistence of warm
autoantibodies and high titer cold agglutinins). However,
there is increasing evidence of atypical cases of difficult
classification, mainly DAT-negative, which are frequently
severe and refractory/relapsing after several therapy lines
and may have a fatal outcome [1–3]. In addition, there are
rare cases caused by IgM autoantibodies with a thermal
activity close to physiological temperatures (warm IgM),
characterized by a severe course and a reportedmortality rate
of about 20% [4]. AIHA can be primary or secondary to lym-
phoproliferative syndromes, infections, immunodeficiency,
and tumors and is described with increasing frequency
following hematopoietic stem cell transplantation (HSCT).
Moreover, coexisting causes of anemia can make the differ-
ential diagnosis quite challenging, and many confounders
may be present at the same time, such as vitamin deficit or
dysmyelopoiesis, altering the peripheral blood picture in a
hemolytic patient. Furthermore, comorbidities may affect the
clinical presentation, for instance, liver disease (decreased
production of hemolytic markers) and renal impairment
(insufficient erythropoietin production).
Several markers or hemolysis (Table 1) have been de-
scribed, which are variably altered in the different forms of
hemolytic anemia, thus helping in the differential diagnosis
and in evaluating the efficacy of treatment. In this review, the
main biochemical hemolytic markers are discussed, focusing
on the differential diagnosis, the correlation with disease
activity, and the response to therapy, with a particular focus
on AIHA.
2. Hemolytic Markers
2.1. Hemoglobin. Hemoglobin is the most direct indicator of
clinical severity in hemolytic diseases. Its levels may be close
to normal values inmild forms (Hb > 10 g/dL) or importantly
reduced in moderate (Hb 8–10 g/dL), severe (Hb 6–8 g/dL),
and very severe (Hb 6 g/dL) forms [5]. In a recent large ret-
rospective study of 308 cases of primary AIHA, hemoglobin
values at diagnosis were the most important predictor of out-
come, correlating with the risk of death and the requirement
of multiple therapy lines [2]. In the differential diagnosis
an acute onset is more frequently observed in RBC enzy-
mopathies involving the pentose phosphate (PP) shunt (e.g.,
glucose-6-phosphate-dehydrogenase, G6PD deficit) and in
autoimmune hemolytic forms involving complement activa-
tion (AIHA caused by warm IgM, warm IgG + C, mixed, and
CADwith thermal range close to physiological temperatures)
and in paroxysmal nocturnal hemoglobinuria (PNH). A
chronic course with possible acute exacerbations is more
commonly found in RBC membrane defects (e.g., hereditary
spherocytosis, hereditary stomatocytosis), enzymopathies of
the nucleotide and glycolytic metabolism (e.g., pyruvate-
kinase deficiency), cold AIHA, and prosthetic cardiac valves
or intravascular devices. A rapid decrease in hemoglobin
values usually leads to relevant symptoms (e.g., asthenia,
tachycardia, and dyspnea), whereas a chronic and progressive
decrease is usually well tolerated. Generally, RBC destruction
rate is much higher in intravascular hemolysis, calculated
as 200mL of RBC in 1 hour, whereas RBC destruction in
extravascular hemolysis is 10-fold less [1].
Hemoglobin levels should be closely monitored in
hemolytic patients and are pivotal for treatment response
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Table 1: Markers of hemolysis in different hemolytic diseases.
AIHA Membrane/enzyme defects CDA PNH TMA Intravascular devices
Hb − to − − − −/−− −−/− − − −−/− − − −−/− − − −
Reticulocytes − to +++ + to +++ −/= − to ++ + +
Schistocytes = = = = ++ +
LDH +/++ + + +++ ++ ++
Haptoglobin − − − − − − −− − − − − −−
Bilirubin + ++ + + + +
Ferritin =/+ ++ +++ − to + =/+ =/+
PLT =/−− =/− = =/− −− =/−
WBC = = = =/− = =/−
Hemosiderinuria =/+ = = + to +++ =/+ =/+
Values are expressed in a semiquantitative style to indicate the different intensity of alteration in the various hemolytic syndromes, as follows: +/++/+++ indicate
an increase from mild to severe, −/−−/− − − indicate a reduction, and = indicates values within the normal range.
AIHA: autoimmune hemolytic anemia; CDA: congenital dyserythropoietic anemia; PNH: paroxysmal nocturnal hemoglobinuria; TMA: thrombotic
microangiopathies; Hb: hemoglobin; LDH: lactate dehydrogenase; PLT: platelets; WBC: white blood cells.
evaluation. In AIHA the response to therapy is usually
defined as “complete” forHb> 12 g/dL and hemolyticmarkers
normalization or “partial” for Hb levels > 10 g/dL or 2 g/dL
increase and reduction of hemolytic markers with no trans-
fusion need [2, 6].
2.2. Reticulocytes. Reticulocytes are nonnucleated direct pre-
cursors of RBC, presenting increased mean corpuscular
volume and a basophilic cytoplasm due to ribosomal-RNA
traces. They represent a small fraction of peripheral RBC
(normal values are about 1%; normal rangemay vary between
laboratories).
Reticulocytes are an index of bone marrow hemopoietic
activity and are usually increased in hemolysis, as well as in
other pathological and physiological conditions (e.g., hem-
orrhage pregnancy, delivery, and acclimation). In hemolytic
conditions, however, the compensatory reticulocytosis may
be inadequate or absent in the presence of concomitant mar-
row involvement (oncohematologic conditions, dyserythro-
poietic or bone marrow failure syndromes), iron and vitamin
deficiency, infections, or autoimmune reaction against bone
marrow-precursors. The latter is of particular interest in
AIHA,where reticulocytopenia is reported in 39%of children
[7] and about 20% of adults [2, 8]. Reticulocytopenia may
often represent a clinical emergency with an extremely high
transfusion need and a poor outcome, as recently shown in 13
very severe, refractory, and fatal AIHA cases [3]. Therefore,
reticulocytes should be evaluated as absolute number or with
the recently proposed bone marrow responsiveness index
(BMRI) [patient’s absolute reticulocyte count × (patient’s
Hb/normal Hb)]. This index with a cutoff value of <121 is
able to discriminate hemolysis with concomitant inadequate
reticulocytopenia with a sensitivity of 90% and specificity of
65% in 205 patientswith congenital dyserythropoietic anemia
type II [9].
Reticulocytosis is an important marker to monitor recov-
ery from hemolysis or response to specific therapy. The
reticulocyte response typically requires 3 to 5 days to occur, as
observed in case of supplementation with folate, B12 vitamin,
or iron in patientswith a deficiency (the so-called reticulocyte
crisis). In AIHA reticulocytes usually remain elevated for
several days until hemoglobin levels are restored; in patients
with inadequate reticulocytosis, erythropoietin has been
shown to improve anemia and to reduce/avoid hemolysis
related to overtransfusion, as observed with thrombopoi-
etin agonists in primary immune thrombocytopenia [2, 10].
In chronic/congenital hemolytic conditions, reticulocytes
are usually mildly elevated but can dramatically rise in
acute hemolytic crisis. In hereditary spherocytosis absolute
reticulocyte counts significantly decrease after splenectomy,
consistently with the reduced hemolytic condition [11]. At
variance, this does not occur in pyruvate-kinase deficit, where
a persistent increased reticulocyte count is observed after
splenectomy [12]. Likewise, in patients with PNH, the retic-
ulocyte counts often remain elevated during treatment with
eculizumab, because of the persistence of some extravascular
hemolysis due to deposition of C3 fragments on PNH red
cells [13]. Finally, reticulocyte count does not significantly
change in patients with prosthetic valve replacement, as this
condition usually implies subclinical hemolysis with normal
or slightly decreased hemoglobin levels [14].
2.3. Schistocytes. A schistocyte is a fragmented part of a RBC,
which is visible at peripheral blood smear as an irregularly
shaped body with two pointed ends without central pallor.
Schistocytes derive from amechanical fragmentation of RBC
due to an obstacle within the vessels, such as fibrin clots,
mechanical artificial heart valve, or any other intravascular
devices. In healthy individuals, normal schistocyte count is
below 0.5%. A count superior to 1% is typical of thrombotic
thrombocytopenic purpura (TTP) with a common range of
3–10%, whereas a value between 0.5% and 1% is sugges-
tive of disseminated intravascular coagulation (DIC). Once
intravascular devices and DIC are excluded, the differen-
tial diagnosis encompasses thrombotic microangiopathies,
caused by hemostasis activation in the small vessels with
consumption of platelets, coagulation factors, and RBC.
In TTP, aberrant hemostasis occurs because of congenital
or acquired deficiency of ADAMTS 13, a metalloproteinase
responsible for von Willebrand multimers degradation.
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Other causes of thrombotic microangiopathies are typical
hemolytic uremic syndrome (HUS), due to Shiga-like toxin
activity, and atypical HUS, caused by aberrant complement
activation. Because in these diseases an intravascular hemol-
ysis occurs LDH values are usually increased. Moreover, in
a pregnant woman with hemolytic anemia, arterial blood
pressure, platelets levels, and liver enzymes should be eval-
uated as hemolysis with elevation of liver enzymes and low
platelets (HELLP) syndrome may occur. Other important
features for the differential diagnosis are proteinuria and
renal impairment (more pronounced in HELLP, typical
and atypical HUS), undetectable ADAMTS 13 activity and
neurological symptoms (common in TTP), and history of
E. coli diarrhea (hallmark of typical HUS) [15]. Blood smear
examination should be early performed to detect schistocytes
if microangiopathic hemolytic anemia is suspected. In fact, a
prompt treatment of these diseaseswithin the first hours from
the diagnosis dramatically decreases their mortality. This is
observed inTTP,wheremortality is reduced to approximately
10% if large volume plasma exchange (60mL/Kg) is started
as soon as the diagnosis is suspected and continued every
day until platelets recovery.The same has been demonstrated
for atypical HUS, where eculizumab may be used, and for
HELLP, which readily improves after delivery induction [15,
16].
2.4. Lactate Dehydrogenase. Lactate dehydrogenase (LDH)
is an enzyme that catalyzes the conversion of lactate into
pyruvic acid, located in cytoplasm and distributed in var-
ious organs (e.g., heart, muscle, liver, and brain). LDH is
physiologically measurable in serum due to physiological
cellular turnover and 5 isoenzymes are present. In particular,
LDH-1 and LDH-2 isoenzymes are expressed in RBC. In
the hemolytic conditions, LDH (mainly isoenzymes 1 and
2) is often increased and may be useful to distinguish
extravascular versus intravascular hemolysis, being slightly
increased in the former (e.g., warm AIHA and congenital
forms) and 4-5-fold the upper normal limit in the latter (e.g.,
PNH, prosthetic valve hemolysis). In patients with AIHA,
higher LDH levels were observed in warm IgG + C and cold
forms with a thermal range close to 37∘C, where intravascular
hemolysis is due to complement activation and correlates
with clinical severity and thrombotic events [2].
Moreover, in patients undergoing prosthetic valve
replacement, LDH was significantly more increased in
patients with mechanic than biologic prosthetic valve and in
those with double than single valve replacement [14]. Finally,
it is worth reminding that LDHmay significantly rise in case
of acute hemolytic crisis due to infections in patients with
congenital hemolytic anemia.
LDH is useful in evaluating response to treatment, as its
level decreases along with the reduction of the hemolytic rate.
This has been described in AIHA, atypical HUS and PNH
following therapy [1, 17], and microangiopathic hemolytic
anemia after plasma exchange [18].Moreover, in patients with
PNH under eculizumab, breakthrough intravascular hemol-
ysis and a return of PNH symptoms may typically occur 1 or
2 days before the next scheduled dose.This is associated with
a spike in the LDH level, suggesting shortening the interval
between administrations or an increase in eculizumab dose
[17]. Because of its large distribution, LDH can increase in
several conditions other than hemolysis, which involve cellu-
lar necrosis and increased tissue turnover (e.g., myocardial
infarction, heart failure, hepatitis of all etiologies, extreme
muscular effort, and solid and hematologic tumors). Very
recently, a ratio between LDHand aspartate aminotransferase
above 22.12 has been shown to differentiate TTP from
other thrombotic microangiopathies (e.g., HUS and HELLP
syndrome) even before ADAMTS 13 activity test results
[15]. Moreover, LDH levels may be markedly increased in
patients with vitamin B12 or folic acid deficiency, because of
ineffective erythropoiesis and premature RBC death.
2.5. Haptoglobin. Haptoglobin (Hp) is a glycoprotein syn-
thetized by the liver sorting within alpha-2 globulins at
serum electrophoresis. It has antioxidant and immunomod-
ulatory properties [19] and acts as a scavenger by sta-
bly binding free serum circulating hemoglobin released by
hemolysis or normal RBC turnover. The resulting com-
plexes are promptly cleared by reticuloendothelial system
via CD163 receptors, preventing the generation of reactive
oxygen species and renal damage. After endocytosis, the
haptoglobin-hemoglobin complex is degraded by lysosomes
resulting in haptoglobin depletion [20]. Haptoglobin is not
a homogeneous protein as there are two common alleles,
called Hp1 and Hp2. This leads to three possible variants (1-
1, 2-2, and 1-2) with different molecular weight polymers,
distinguishable at high resolution electrophoresis, which
show different behavior in their shielding against oxidative
stress [21].
Haptoglobin is significantly decreased during hemolysis,
[22] both in intravascular forms, due to increased free
plasma Hb and altered free/complexed haptoglobin balance,
and in extravascular cases, where little intravascular lysis
of structurally altered RBC escaped from reticuloendothe-
lial clearance may be present [23]. In AIHA haptoglobin
represents the most sensitive marker of hemolysis and it is
the last one to normalize after recovery, possibly remaining
decreased even in the presence of normal Hb levels (personal
observation).
Concerning the differential diagnosis, reduced levels of
haptoglobin are observed in conditions other than hemol-
ysis, such as liver impairment, malnutrition, and congeni-
tal hypohaptoglobinemia. On the other hand, haptoglobin
increases in inflammatory diseases, in cigarette smokers,
and in nephrotic syndrome, possibly masking an underlying
hemolytic condition. In a study of 100 patients with a
variety of hematologic and nonhematologic diseases, a hap-
toglobin limit of 25mg/dL or less allowed the identification
of hemolytic from nonhemolytic disorders with a sensitivity
and specificity of 83% and 96%, respectively [24].
2.6. Bilirubin. Bilirubin IXa derives from the catabolism of
the protoporphyrin IX ring of heme, the prosthetic group of
proteins involved in oxygen transport and metabolism (e.g.,
Hb,myoglobin, and cytochrome P450) bymicrosomal heme-
oxygenase. 85% of the circulating bilirubin derives from
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hemoglobin catabolism in the reticuloendothelial organs.
Ineffective erythropoiesis in the bone marrow, which is
present at low rate in physiological conditions, constitutes an
additional bilirubin source. Bilirubin is a good marker for
extravascular and, to a lesser extent, also for intravascular
hemolysis, where aminor fraction of the released heme binds
to hemopexin and undergoes reticuloendothelial catabolism
in the liver. Bilirubin, produced in the periphery, is trans-
ported to the liver tightly bound to albumin (namely, uncon-
jugated bilirubin). In the liver bilirubin is converted to biliru-
bin mono- and diglucuronides by the microsomal enzyme
bilirubin UDP-glucuronosyltransferase and then is excreted
with the bile (conjugated bilirubin). Increased bilirubin levels
may therefore be due to increased hemoglobin catabolism
(mainly resulting in unconjugated hyperbilirubinemia) or
to decreased hepatic clearance (most commonly conjugated
hyperbilirubinemia). Bilirubin upper normal limit should
be corrected for variations in the circulating RBC mass, by
dividing patient’s hematocrit by 45, so that in patients with
reduced hematocrit a little bilirubin increase may already be
considered pathological. Hyperbilirubinemia during hemol-
ysis is usually no more than 4mg/dL, and higher values
almost always imply a concomitant reduction in the hepatic
function, which can be easily investigated by liver functional
markers. Unconjugated values greater than 4mg/dL are
however observed in acute massive hemolysis (e.g., G6PD
deficiency or transfusion reactions) [25] and in the case of
coexisting Gilbert’s syndrome, reported in 5% of the general
population and characterized by a reduction in the activity of
the hepatic bilirubin UDP-glucuronosyltransferase [26].
Bilirubin is an early marker of therapy response as it
returns to normal or within 10% of normal values in 4
hours after hemolysis cessation. In AIHA a reduction of
unconjugated bilirubin concentration is observed already on
the 7th day of steroid therapy, providing early evidence of
therapeutic response [25]. Moreover, levels of unconjugated
bilirubin significantly decreased after splenectomy in heredi-
tary spherocytosis [11], and total circulating bilirubin tends to
decrease in patients with PNH treated with eculizumab [17].
2.7. Ferritin. Ferritin is an intracellular protein that stores
iron and releases it in case of request, acting as a buffer
against iron deficiency and iron overload. It may be used
as an indirect marker of the total body amount of iron.
Ferritin is increased in several chronic hemolytic conditions,
such as congenital membrane defects and enzymopathies,
chronic cold agglutinin disease, and congenital dyserythro-
poietic anemia [9, 11, 12]. Although the precise mechanism
leading to its increase has not been investigated, it has been
hypothesized that iron produced by ineffective erythropoiesis
and extravascular hemolysis is not easily eliminated and that
anemia itself is a powerful stimulus for iron absorption in the
gut. Patients with PNH may display either increased ferritin
valueswhenunder eculizumab treatment probably because of
continuous extravascular hemolysis (personal observation)
or reduced ferritin levels due to hemosiderinuria and iron loss
[17]. Ferritin is an acute phase protein and increases in vari-
ous metabolic and inflammatory diseases (e.g., chronic and
acute infections, hepatitis, and tumors).Thus the coexistence
of these conditions together with chronic hemolysis may
give rise to particularly high ferritin values. Moreover iron
overload is observed after transfusion and in patients with
hereditary hemochromatosis. The presence of an undiag-
nosed heterozygous condition for hemochromatosis may
further increase hyperferritinemia due to chronic hemolysis.
In hereditary spherocytosis a serum ferritin concentration >
500 ng/mL was detected in 8 out of 189 nonsplenectomized
and never transfused patients, and 3 of them were found to
have the hemochromatosis His63>Aspmutation in heterozy-
gosity [11]. Finally, transfusion support, which is often given
to hemolytic patients, may also contribute to iron overload.
2.8. Other Complete Blood Count Abnormalities. Among
the several alterations of blood counts observed in the
different hemolytic diseases considered, the possible reduced
leukocytes and platelets in B12 and folic acid deficiency are
worth reminding. Moreover, the presence of thrombocy-
topenia suggests a possible thrombotic microangiopathy or
Evans’ syndrome. The latter should be promptly recognized
and treated, as it has been recently reported as a negative
prognostic factor in patients with AIHA [2]. Leukocytes
and platelets may also be slightly reduced in patients with
PNH, as these cells are deficient for CD55/CD59 molecules
and they may be damaged by complement activation. More
pronounced leucopenia and thrombocytopenia occur in
case of PNH-associated bone marrow failure syndromes.
In patients with congenital membrane or enzyme defects
mild thrombocytopenia may be related to hypersplenism,
whereas thrombocytosis may be observed after splenectomy.
Finally, platelets and leukocytes may also be destroyed by
intravascular devices.
2.9. Hemosiderinuria. Hemosiderinuria is the presence of
hemosiderin bound to iron in the urine and accounts for
the “brownish” color of urine, typically associated with
marked intravascular hemolysis. Hemoglobin released into
the bloodstream in excess of haptoglobin binding capacity
is filtered by the kidney and reabsorbed in the proximal
convoluted tubule. Here, the iron portion is removed and
stored as ferritin or hemosiderin and then excreted into the
urine. Hemosiderinuria is typically observed in PNH, incom-
patible RBC transfusion, G6PD deficiency, severe burns, and
infections. It is usually seen 3-4 days after the onset of
hemolysis and it can persist for several weeks after hemolysis
cessation, whereas hemoglobinuria quickly disappears.
2.10. Treatment of AIHA. The distinction between warm
AIHA and CAD is fundamental, as the two forms have
quite different responses to the available therapies. For
warm AIHA steroids represent the first-line therapy [1]:
oral prednisone is usually given at 1–1.5mg/kg/day for 1–3
weeks until hemoglobin >10 g/dL and then slowly tapered
off over a period not shorter than 4–6 months. Intravenous
methylprednisolone 100–200mg/day for 10–14 days or 250–
1000mg/day for 1–3 days may be indicated in very severe
or complex cases such as Evans’ syndrome. Steroids are able
to provide a response in 70–85% of patients, but with an
estimated cure rate in 20–30%only. Second-line treatment for
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warm forms includes splenectomy [27] (early response rate
in ∼70% and a presumed curative rate in ∼20% of cases but
associated with infective and thrombotic risk) and rituximab,
which is increasingly preferred (response rate of about 70–
80% and disease-free survival of ∼70% at one and ∼55%
at two years) [28]. Conventional immunosuppressive drugs
(such as azathioprine, cyclophosphamide, and cyclosporine)
are mostly used as steroid-sparing agents when splenectomy
is not feasible and/or rituximab unavailable. Response rates
are reported in 40–60% but partially attributable to con-
comitant steroid administration, and serious side effects are
not infrequent [1, 27]. Further treatments include mycophe-
nolate and for the few ultra-refractory patients high dose
cyclophosphamide, alemtuzumab, plasma exchange, and ery-
thropoietin, particularly in the presence of reticulocytopenia.
Cold agglutinin disease deserves treatment in the presence
of symptomatic anemia, transfusion dependence, and/or dis-
abling circulatory symptoms. Steroids are now discouraged,
as they are effective at unacceptably high doses and in a
small fraction of cases (14–35%), and splenectomy is usually
unsuccessful [1, 29]. Rituximab is now recommended as the
first-line treatment, being effective in ∼60% of cases (5–
10% complete responses), with a response duration of 1-
2 years [30]. For refractory/relapsing cases other options
are rituximab plus fludarabine, bortezomib, and eculizumab,
although further studies are required to confirm their efficacy.
Future promising drugs are the new complement inhibitors
TNT003, C1-esterase inhibitors, compstatin Cp40, and TT30
[31].
3. Conclusion
Hemolytic anemia contains a group of heterogeneous dis-
eases both congenital and acquired in which the diagnosis
may be challenging. Blood smear examination is still funda-
mental, andDAT is the cornerstone for the diagnosticworkup
of acquired forms but may be affected by various drawbacks.
Hemolytic parameters may be differently altered in the
various conditions thus helping the differential diagnosis.
However, many confounders may further complicate the
clinical picture, underlining the need for a comprehensive
clinical and laboratory evaluation. Finally, hemolyticmarkers
are undoubtedly important in monitoring the efficacy of
treatment.
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